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Abstract
Objective: Published studies in adult and pediatric bipolar disorder have used different definitions of treatment response. This
analysis aimed to compare different definitions of response in a large sample of children and adolescents.
Methods: Anexploratory analysis of a 4-week, multicenter, placebo-controlled study assessed patients (n = 296; ages, 10–17
years) with an acute manic/mixed episode associated with bipolar I disorder who were randomized to aripiprazole (10 or
30 mg/day) or placebo. The primary efficacy endpoint was mean change from baseline to week 4 in Young Mania Rating
Scale (YMRS) total score. Additional assessments included: Clinical Global Impressions–Bipolar Disorder (CGI-BP)
Overall and Mania scales, Child Global Assessment Scale (CGAS), and parent and subject General Behavior Inventory.
Response was compared across seven operational definitions. Cohen’s j and Spearman’s correlation tested relationships
between various response definitions or changes in outcome measures and clinically meaningful improvement (defined as a
CGI-BP Overall Improvement score of 1 or 2).
Results: Response rates varied depending upon the operational definition, but were highest for 95% reliable change (sta-
tistical method used to determine individual change from previous assessment) and ‡ 33% reduction in YMRS total score.
Response rate definitions with the highest validity in terms of predicting clinically meaningful improvement were: ‡ 50%
reduction on YMRS (j = 0.64), a composite definition of response (YMRS < 12.5, Children’s Depression Rating Scale-
Revised (CDRS-R) £ 40, and CGAS ‡ 51; j = 0.59), and 95% reliable change on the CGAS or 33% reduction on YMRS
(j = 0.56). Parent ratings of symptoms were generally better at detecting symptom improvement than were subject ratings
(j =*0.4–0.5 vs. *0.2 when compared with CGI-BP Overall Improvement score).
Conclusions: Clinically meaningful definitions of response in acute treatment of a manic/mixed episode in pediatric subjects
include a 50% change in YMRS and a composite measure of response. Parent-reported measures of symptom improvement
appear reliable for assessing symptom change.
Introduction
Pediatric bipolar disorder is a serious mental health illnessthat disrupts the lives of patients and their families. Although the
exact prevalence of pediatric bipolar disorder is not known, a recent
meta-analysis of community epidemiological studies indicates that
bipolar spectrum conditions may affect 2% of children and adolescents
around the world (Youngstrom et al. 2010; Van Meter et al. 2011).
Validated measures of symptom severity, such as the Young
Mania Rating Scale (YMRS) (Young et al. 1978), are commonly
used to evaluate the efficacy of pharmacologic treatment in clinical
trials of bipolar disorder in both children and adults. However,
published studies in adult and pediatric populations have used
different definitions of response, which can increase the difficulty
in comparing results across studies. Proposed definitions vary from
a 33% or 50% reduction in symptoms (measured using the YMRS)
to more complex definitions that combine scale scores with
measures of overall functional outcomes (Kowatch et al. 2000;
Kafantaris et al. 2001; Findling et al. 2003).
In addition to the more standard approaches mentioned, an in-
teresting model that is widely used in studies of psychosocial
interventions has been developed to evaluate clinically significant
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change ( Jacobson and Truax 1991; Atkins et al. 2005). This
method, proposed by Jacobson and Truax, involves a two-step
approach that focuses on whether there is a reliable change be-
tween an individual’s pre- and post-treatment functioning on a
given outcome measure, plus comparison against normative
benchmarks (three cutoff criteria, defined as A [move the patient
Away from the clinically impaired range of functioning]; B [move
the patient Back into the normal range of functioning]; and C [move
the patient Closer to the normal than the clinically impaired
range of functioning]). Reliable change is a difference in the in-
dividual’s scores considered large enough that it is unlikely to be
caused by imprecision in the measure. Jacobson and colleagues
have suggested using a 95% confidence interval (CI) constructed
using the standard error of the difference score for the measure as a
way of operationally defining reliable change. They suggested
setting the normative benchmarks at two standard deviations (SD)
below average for the clinical population of interest (the Away
benchmark, assuming that high scores reflect greater pathology)
and two SDs around the nonclinical mean on the same measure. The
third benchmark is usually operationally defined as the weighted
average of the clinical and nonclinical means from the normative
groups, taking into account the possibility that the two groups
have different variations in scores. The choice of a 95% CI for the
reliable change index, and the use of a two SD threshold for
the benchmarks, has become an established convention to align with
the a level of 0.05 norm in statistical significance testing.
The Jacobson and Truax approach permits classification of in-
dividuals into one of four categories: recovered – reliable change
moving past one of the normative benchmarks; improved – reliable
change, but not yet sufficiently great to pass a normative bench-
mark; unchanged – when score movement is too small to surpass
the reliable change threshold imposed by the precision of the in-
strument; or deteriorated – when there is reliable change for the
worse (Atkins et al. 2005; Youngstrom et al. 2008). A major dif-
ference between the Jacobson and Truax method and conventions
focusing on effect size is that, with the former, clinically significant
individual outcomes, rather than an average effect across cases, are
evaluated. All of the benchmarks were constructed for each po-
tential outcome measure, as one of the major aims of this article was
to compare the alternate definitions of change and treatment re-
sponse across measures. We believe that improved understanding
of clinically meaningful improvement in symptoms is of value to
researchers, as well as to clinicians.
Since its introduction, a variety of refinements and alternatives
have been proposed to the basic Jacobson and Truax model. Some
are modifications to further enhance the psychometric properties;
for example, by adjusting the standard errors to reflect changes in
precision across different score ranges (Speer 1992). However,
these methods are more complex and do not always improve per-
formance (Ogles et al. 2001). A second alternative is the use of
mixed regression models or growth curve models to estimate in-
dividual trajectories of change (Speer et al. 1995). Although mixed
regression or growth curve models are conceptually attractive in a
variety of ways, they are challenging for practicing clinicians to
estimate, and difficult or impossible to apply to individual cases.
They also do not map onto metrics such as the number needed to
treat (NNT), which evidence-based medicine uses to evaluate trials
and apply results to individual patients (Guyatt and Rennie 2002;
Straus et al. 2011). A third approach is to use the equivalence
testing framework (Westlake 1976) to evaluate whether the post
treatment distribution is negligibly different from nonclinical dis-
tributions (Kendall et al. 1999). This method has conceptual appeal
as a complement to group effect size estimation, but it remains a
group-oriented summary itself that cannot be applied by clinicians
to individual cases (Follette and Callaghan 2001). Experts have
pointed to the need to evaluate consumer satisfaction and quality of
life as important components of clinically significant outcomes, in
addition to measures of symptom reduction (Kazdin 1999). Of the
different definitions of clinically significant change in symptoms,
the Jacobson model is the one to accrue the most evidence for
corresponding with satisfaction and improved functioning (Ankuta
and Abeles 1993; Lunnen and Ogles 1998). For all of these reasons,
the ‘‘classic’’ Jacobson and Truax method has remained the dom-
inant model in psychotherapy trials, and, therefore, was our choice
for comparison with the operational definitions used in prior
pharmacological trials in pediatric bipolar disorder.
Currently, no consensus has been established regarding any
particular definition of response as a measure of clinically signifi-
cant change in the treatment of manic or mixed episodes associated
with bipolar I disorder in either the adult or pediatric patient pop-
ulation. The purpose of this secondary analysis was to compare
different definitions of response in a large sample of children and
adolescents (ages 10–17 years) who had participated in a 4-week
trial of aripiprazole (10 or 30 mg/day) for the treatment of an acute
manic or mixed episode associated with bipolar I disorder (Findling
et al. 2009). In these analyses, simultaneous comparisons were
made across multiple outcome measures using a range of defini-
tions of response in order to evaluate which definitions of response
may be most relevant to clinical practice. One goal was to explore
whether any definitions were consistently more liberal or conser-
vative across the various outcome measures. A second goal was to
examine whether any measures appeared particularly sensitive or
unresponsive to treatment effects. Because different studies have
selected varying definitions of response, comparing these opera-
tional definitions in a single sample provides an important sense of
how the definitions are calibrated against each other.
Methods
Study design and patients
This was a secondary analysis of a 4-week, multicenter, placebo-
controlled, randomized study of the efficacy and safety of aripi-
prazole 10 or 30 mg/day in children and adolescents (n = 296; ages,
10–17 years) with an acute manic or mixed episode associated with
bipolar I disorder. The study enrolled patients across 59 sites in the
United States between March 2005 and February 2007. Study
procedures were adherent to the Declaration of Helsinki and In-
ternational Conference on Harmonization/Good Clinical Practice
Guidelines, and were approved by the institutional review boards at
each site. All parents/guardians provided written informed consent
to participate, and subjects provided written, informed assent when
possible.
Detailed information on the study design and patient popula-
tion has been published previously (Findling et al. 2009). Briefly,
the study population consisted of children and adolescents with a
confirmed Diagnostic and Statistical Manual of Mental Dis-
orders, 4th ed. (DSM-IV) diagnosis of bipolar I disorder with
current manic or mixed episodes (American Psychiatric Asso-
ciation 1994), with or without psychotic features, and a YMRS
total score ‡ 20 at baseline. Subjects were diagnosed by a board-
certified or board-eligible child and adolescent psychiatrist and
the diagnosis was confirmed using the Kiddie Schedule for Af-
fective Disorders and Schizophrenia (Kim et al. 2004). Subjects
with comorbid attention-deficit/hyperactivity disorder (ADHD),
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conduct disorder, oppositional defiant disorder, or anxiety disorders
(except posttraumatic stress disorder or obsessive-compulsive dis-
order) were also eligible.
Assessments
The primary efficacy outcome measure was the mean change
from baseline to endpoint (week 4) in the YMRS total score. During
the study, patients, parents, and clinicians completed additional
rating scales at baseline and at each study visit up to week 4, in-
cluding: the Clinical Global Impressions–Bipolar Disorder (CGI-
BP) Overall, – Depression, and – Mania Improvement and Severity
scores (Spearing et al. 1997); Children’s Depression Rating Scale-
Revised (CDRS-R) (Poznanski and Mokros 1995); Children’s Glo-
bal Assessment Scale (CGAS) (Shaffer et al. 1983); and parent- and
subject-rated 10-item versions of the General Behavior Inventory
Mania (parent/subject-GBI-M10) and Depression (parent/subject-
GBI-D10) (Youngstrom et al. 2001; Danielson et al. 2003) scales.
GBI items were scaled from 0 to 3; therefore, scores could range
from 0 to 30 points. Further details on efficacy and safety assess-
ments undertaken in the study have been published elsewhere
(Findling et al. 2009).
Definitions of response
Response, as measured by change from baseline in YMRS total
score, was defined according to one of seven different operational
criteria: 1) 33% reduction from baseline in YMRS total score; 2)
‡ 50% reduction from baseline in YMRS total score; 3) 95% reli-
able change ( Jacobson and Truax 1991); 4) reliable change plus
moving more than two SDs away from the clinically impaired range
of functioning for bipolar disorder cases ( Jacobson and Truax
definition A, Away from the clinical distribution; Fig. 1; [Jacobson
and Truax 1991]); 5) reliable change plus moving back within two
SDs of the nonclinically impaired, that is, normal functioning mean
( Jacobson and Truax definition B, Back within the nonclinical
range; Fig. 1; [Jacobson and Truax 1991]); and 6) reliable change
plus moving closer to the nonclinically impaired than the clinically
impaired range of functioning ( Jacobson and Truax definition C,
Closer to nonclinical than clinical levels; Fig. 1; [Jacobsonand
Truax 1991]).
The seventh response definition composite (COMP) comprised
a composite of scores achieved on the YMRS (< 12.5), CDRS-R
(£ 40), and CGAS (‡ 51),which has been used previously to de-
fine clinical response in a study of lithium and divalproex sodium
for the treatment of bipolar disorder in pediatric patients (Findling
et al. 2003).
Statistical analysis
Secondary analyses were conducted on the efficacy sample, which
consisted of patients who had received at least one dose of study
treatment and had had at least one post baseline efficacy assessment.
Rates of response were derived from the number of individual cases
meeting each operational definition of change over the total number
of cases evaluated for that change. Rates were estimated separately
for the placebo and aripiprazole 10 mg and 30 mg treatment arms.
The NNT (Straus et al. 2005) compared response rates with
aripiprazole 10 mg/day versus placebo, and aripiprazole 30 mg/day
versus placebo separately. The absolute rates indicated which defi-
nitions produced more liberal or conservative rates of response,
whereas the NNT focused on the extent to which active treatment
differentiated from placebo response. Two sets of analyses quantified
the criterion validity of each operational definition of individual
improvement compared with the clinical global impressions of
change; a CGI-BP Overall Improvement score of 1 or 2 (‘‘very much
improved’’ or ‘‘much improved,’’ respectively) was specified a priori
as a clinically relevant benchmark of symptom improvement. Kappa-
measured agreement above chance with a dichotomized ‘‘improved,
yes or no’’ standard (Cohen 1960) and Spearman’s correlation
quantified agreement with an ordinal scale of degree of improvement
(Well and Myers 2003). All analyses were conducted using the last
observation carried forward approach and were descriptive in nature;
formal statistical comparisons were not conducted.
Results
Patient population
A total of 296 subjects were randomized and included in the
efficacy sample: aripiprazole 10 mg/day, n = 98; aripiprazole
30 mg/day, n = 99; placebo, n = 99. Of these, 237 (80.1%) com-
pleted the 4-week study (Findling et al. 2009).
Baseline demographic characteristics of subjects in each treat-
ment group are shown in Table 1, and have been published previ-
ously (Findling et al. 2009). In brief, the overall study population
had a mean age of 13.4 years and was predominantly white (65.2%)
and male (53.7%) (Findling et al. 2009). Acute treatment yielded
moderate-to-large group effect sizes (Cohen’s d values of 0.60 and
0.93 for aripiprazole 10 and 30 mg/day, respectively) for im-
provement in the CGI-BP Overall Improvement score, the main
criterion for examining the validity of differing operational defi-
nitions of clinically significant change in the present analyses.
Response rates by differing levels of response
The proportions of subjects achieving response to aripiprazole
10 or 30 mg/day or placebo according to predefined thresholds of
symptom improvement are presented in Figure 2.
Response rates varied substantially across operational defini-
tions. Utilizing a response definition of ‡ 33% reduction in YMRS
total score, rates were > 70% for both aripiprazole 10 (73%,
NNT = 3) and 30 (77%, NNT = 3) mg/day and 38% for placebo,
whereas the magnitude of response to treatment with aripiprazole
or placebo was generally lower when the more stringent definition
FIG. 1. Jacobsen and Truax definitions of response ( Jacobson
and Truax 1991). A ( Jacobson and Truax definition A): reliable
change plus moving more than two standard deviations (SDs)
Away from the impaired range of functioning; B ( Jacobson and
Truax definition B): reliable change plus moving Back within two
SDs of the impaired, that is, in the normal functioning mean; C
( Jacobson and Truax definition C): reliable change plus moving
Closer to the normal functioning than to the impaired range of
functioning.
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of ‡ 50% reduction in YMRS total score was applied (45%
[NNT = 5] or 64% [NNT = 3] for aripiprazole 10 or 30 mg/day,
respectively; 25.5% for placebo).
The Jacobson and Truax criterion of 95% reliable change re-
sulted in the highest response rates; 88% (NNT = 6) and 91%
(NNT = 5) being observed in the aripiprazole 10 and 30 mg/day
treatment groups, respectively, and 70% in the placebo group.
Conversely, rates of response to aripiprazole did not exceed 30%
using Jacobson and Truax definition A (15% [NNT = 9]; 27%
[NNT = 4]), B (5% [NNT = 19]; 10% [NNT = 10]) or C (5%
[NNT = 19]; 10% [NNT = 10]) for aripiprazole 10 mg/day and
30 mg/day, respectively, whereas placebo response rates were
negligible ( < 3.2%).
Calculation of response derived from COMP of scores achieved
on the YMRS, CDRS-R, and CGAS resulted in response rates of
35% (NNT = 4) and 55% (NNT = 2) in the aripiprazole 10 and
30 mg/day groups, respectively, compared with 13% for placebo.
Criterion validity/agreement
Table 2 presents the results of j tests of agreement between
symptom improvement, defined according to different thresholds
of response, and a CGI-BP Overall Improvement score of 1 or 2.
Overall, the degree of agreement ranged from 0.15 to 0.64 among
the various definitions of symptom improvement applied.
The measure with the highest validity (highest agreement) in
terms of predicting clinician-rated global symptom improvement
was ‡ 50% reduction on the YMRS (j = 0.64) followed by the
composite definition of response (COMP; j = 0.59) and 95% reliable
change on the CGAS or 33% reduction on the YMRS (j = 0.56;
Table 2). Notably, 50% and 33% reduction on the parent version
of the GBI-M10 were associated with a magnitude of agreement
equivalent to j values of 0.48 and 0.43, respectively (Table 2).
Agreement was lowest for measures based on subject self-report,
with j values ranging from 0.20 to 0.25 for S-GBI-M10 and from
0.15 to 0.21 for S-GBI-D10. Additional analyses using CGI-BP
Mania Improvement score as a benchmark (as opposed to CGI-BP
Overall Improvement score) revealed j values that ranged between
0.11 and 0.63. As generally observed for CGI-BP Overall Im-
provement score, highest agreement in terms of predicting mania
symptom improvement was observed for response definitions
comprising at least 50% reduction in YMRS score (j = 0.63), 33%










Mean age, years (SD) 13.7 (2.2) 13.3 (2.3) 13.3 (2.1)
Males/females, (%) 53.1/46.9 51.5/48.5 56.6/43.4
Mean weight, kg (SD) 63.8 (20.1) 60.5 (21.5) 60.5 (17.3)
Race, n (%)
Caucasian 65 (66.3) 68 (68.7) 60 (60.6)
Black 24 (24.5) 18 (18.2) 23 (23.2)
Pacific Islander 2 (2.0) 0 (0.0) 0 (0.0)
Other 7 (7.1) 13 (13.1) 16 (16.2)
Symptom rating scales,
meana
YMRS total score 29.8 29.5 31.1
CGAS 46.9 47.5 45.5










GBI-M (parent) 17.7 17.4 19.1
GBI-M (subject) 15.1 14.8 14.8
GBI-D (parent) 13.4 12.4 13.4




Yes 7 (7.1) 4 (4.0) 3 (3.0)
No 58 (59.2) 58 (58.6) 64 (64.7)
Unknown 33 (33.7) 37 (37.4) 32 (32.3)
History of rapid
cycling, n (%)b
Yes 17 (17.4) 13 (13.1) 15 (15.2)
No 49 (50.0) 46 (46.5) 51 (51.5)
Unknown 32 (32.7) 40 (40.4) 33 (33.3)
aPatient populations in the aripiprazole (10 mg/day), aripiprazole
(30 mg/day), and placebo groups were: 96, 99, and 94, respectively for
YMRS, CGAS, CGI-BP; 91, 94, and 86, respectively, for CDRS-R; 95, 96,
and 93, respectively, for parent versions of GBI-M and GBI-D; and 96, 96,
and 93, respectively, for subject versions of GBI-M and GBI-D.
bThese data were collected post hoc; as capture of data on comorbid
diagnoses was not required by investigators, there is a high percentage of
missing data.
CDRS-R, Children’s Depression Rating Scale-Revised; CGAS, Children’s
Global Assessment Scale; CGI-BP, Clinical Global Impressions–Bipolar
Disorder; GBI-D, General Behavior Inventory Depression; GBI-M, General
Behavior Inventory Mania; YMRS, Young Mania Rating Scale.
FIG. 2. YMRS response rates using different definitions of re-
sponse and composite response (COMP*). *A composite of scores
achieved on the YMRS (< 12.5), CDRS-R (£ 40), and CGAS
(‡ 51) (Findling et al. 2003). COMP, composite response; CDRS-
R, Children’s Depression Rating Scale-Revised; CGAS, Chil-
dren’s Global Assessment Scale; JTA, Jacobson and Truax
efinition A; JTB, Jacobson and Truax definition B; JTC, Jacobson
and Truax definition C; RC, reliable change; YMRS, Young
Mania Rating Scale.
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reduction on the YMRS (j = 0.58) and COMP, or 95% reliable
change on the CGAS (j = 0.53).
Correlations between estimates of change
As shown in Figure 3, the relationship, as determined by cor-
relation coefficients, between change in score on measures of de-
pression and mania symptom severity, and change in CGI-BP
Overall Improvement score, varied across measures. Among these,
Spearman’s rank correlation coefficients with change in CGI-BP
Overall Improvement score were highest for CGI-BP Mania se-
verity score (r = 0.94), CGAS (r = 0.73) and YMRS (r = 0.69), all of
which were ratings made by the clinician based on the same in-
terviews; thus sharing substantial method variance (Campbell and
Fiske 1959). The magnitude of the correlation between measures of
depression severity and CGI-BP Overall Improvement score was
generally lower than for measures of mania (Fig. 3).
Of note, parent-reported versions of GBI-M10 and GBI-D10
demonstrated higher correlations with the CGI-BP Overall Im-
provement score than the corresponding subject-reported versions
(GBI-M10: r = 0.48 vs. 0.29; GBI-D10: r = 0.30 vs. 0.22). Observed
correlations between change in symptom severity scales and
change in mania (as measured using CGI-BP Mania Improvement
score) were highest for CGI-BP Overall Improvement score
(r = 0.94), YMRS (r = 0.72) and CGAS (r = 0.71). Similar to CGI-
BP Overall Improvement score, correlations between change in
measures of depression severity and change in CGI-BP Mania
Improvement score were of a lower order of magnitude (r = 0.21 to
0.45) than measures of mania severity (r = 0.30 to 0.72).
Additional analyses of the correlations between change in par-
ent- and clinician-rated measures on the GBI revealed statistically
significant ( p < 0.05) relationships between the change scores
(parent-GBI-M10: YMRS, r = 0.44; CGI-BP Mania Improvement
score, r = 0.45; CGAS, r = 0.43; and parent-GBI-D10: CGAS,
r = 0.28; CDRS-R, r = 0.37; CGI-BP Depression Improvement
score, r = 0.33).
Discussion
There is a lack of consensus regarding which definitions of re-
sponse for assessment of treatment effects in both adult and pediatric
clinical trials of bipolar disorder are the most clinically relevant.
Available data from a study of nearly 300 children and adolescents
participating in a randomized, placebo-controlled trial of ar-
ipiprazole for the treatment of an acute manic or mixed episode
associated with bipolar I disorder provided an opportunity to conduct
simultaneous comparisons of different definitions of response and
clinically relevant change using multiple outcome measures in order
to explore the significance of observed treatment effects. The com-
parison of multiple operational definitions within the same sample
provides a sort of ‘‘Rosetta Stone’’ to help calibrate results across
multiple studies. Comparing different trials is much more feasible
when they use a shared comparator (e.g., placebo) and consistent
operational definitions of outcome (e.g., Cipriani et al. 2011).
Not unexpectedly, our findings demonstrated considerable var-
iability in response rates based on operational definitions. The
composite algorithm or clinician ratings on the YMRS (a reduction
in total score of ‡ 50%) and CGAS showed the best validity in
terms of predicting a CGI-BP Overall Improvement score of 1 or 2
at endpoint (j = 0.6 for each), which was chosen as the ‘‘bench-
mark’’ for meaningful clinical improvement. As the study popu-
lation was enriched for patients with mania, analyses were also
undertaken using CGI-BP Mania Improvement score as a bench-
mark, and provided comparable results. These observations support
the use of a reduction of ‡ 50% in YMRS total score or a composite
Table 2. Kappa Values Using Various Outcome Measures (with Different Definitions of Response) and CGI-BP
Overall Improvement Score = 1 or 2 as the Benchmark
Response definition YMRS P-GBI-M10 S-GBI-M10 P-GBI-D10 S-GBI-D10 CDRS-R CGAS COMP
33% reduction 0.56 0.43 0.20 0.35 0.21 0.27 0.52 –
‡ 50% reduction 0.64 0.48 0.22 0.33 0.21 0.10 0.37 –
95% reliable change 0.26 0.36 0.24 0.27 0.18 0.24 0.56 –
JTA 0.30 0.24 – – – 0.24 0.52 –
JTB 0.11 0.46 0.20 0.30 0.21 0.27 0.37 –
JTC 0.11 0.43 0.25 0.27 0.15 0.27 0.47 –
COMPa – – – – – – – 0.59
Bold values represent the highest kappa values.
aA composite of scores achieved on the YMRS (<12.5), CDRS-R (£ 40), and CGAS (‡ 51) (Findling et al. 2003).
CDRS-R, Children’s Depression Rating Scale-Revised; CGAS, Children’s Global Assessment Scale; COMP, composite response; JTA, Jacobson and
Truax definition A; JTB, Jacobson and Truax definition B; JTC, Jacobson and Truax definition C; P-GBI-M10/S-GBI-M10, parent/subject 10-item
version of General Behavior Inventory Mania; P-GBI-D10/S-GBI-D10, parent/subject 10-item version of General Behavior Inventory Depression;
YMRS, Young Mania Rating Scale.
FIG. 3. Spearman correlation coefficients (absolute values) for
changes in outcome measures compared with changes in CGI-BP
Overall Improvement score (aripiprazole [10 and 30 mg/day] and
placebo combined). CDRS-R, Children’s Depression Rating Scale-
Revised; CGAS, Children’s Global Assessment Scale; CGI-BPD,
Clinical Global Impressions–Bipolar Disorder Depression severity
score; CGI-BPM, Clinical Global Impressions–Bipolar Disorder
Mania severity score; P-GBI-M10/S-GBI-M10, parent/subject 10-
item version of General Behavior Inventory Mania; P-GBI-D10/
S-GBI-D10, parent/subject 10-item version of General Behavior
Inventory Depression, YMRS, Young Mania Rating Scale.
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measure combining response on mania, depression, and global
functioning (YMRS < 12.5, CDRS-R £ 40, and CGAS ‡ 51) as a
clinically relevant criterion for response in clinical trials for acute
treatment of manic or mixed presentations of pediatric bipolar I
disorder. The Jacobson and Truax definitions were much more
conservative, basically eliminating placebo response. The rates of
clinically significant change were low for active treatment as well,
reflecting that normalization of functioning is a challenging goal for
treatment of bipolar disorder. The NNT for active drug versus
placebo ranged from 2 to 19 depending upon the definition of re-
sponse used. The most liberal definition of response (e.g., 95%
reliable change) had moderate NNT values because of high placebo
response rates, whereas the most stringent Jacobson and Truax
definitions had poorer NNT values because of lower response rates
for active treatment, as well as placebo. The composite definition
produced the most favorable NNT, but the Jacobson and Truax
definitions highlight the difficulty of achieving normalization even
with substantial treatment response.
Although the YMRS and CGAS scales and the CGI-BP Mania
Improvement scores were among the three measures that demon-
strated the highest correlation with change in CGI-BP Overall
Improvement scores, the magnitude of these correlations (0.7–0.8)
suggests that there is incomplete overlap between the symptoms
measured using the various scales, and the symptom improvements
measured by the CGI-BP Overall Improvement score. Conversely,
the CGI-BP, YMRS, and CGAS all share similar methodology (i.e.,
clinician-rated measures based on a combination of interview and
observation). This shared ‘‘source variance’’ ultimately boosts their
correlation with each other, because each is asking the same cli-
nician to make judgments about related aspects of the patient’s
functioning (Campbell and Fiske 1959).
Measurements based on parental responses were generally better
indicators of changes in symptom severity compared with mea-
surements based on subject response. For example, j values denoting
agreement between definitions of symptom improvement and CGI-
BP Overall Improvement were lower when rated by subjects than
when rated by their parents (*0.2 vs. *0.4–0.5); although it
should be noted that these differences were not tested statistically.
This may be largely because of a relative lack of insight on the part of
an adolescent experiencing an acute manic or mixed episode (Pini
et al. 2001; Dell’Osso et al. 2002; Youngstrom et al. 2004). However,
the baseline score of the patient versus parent reports should also be
considered; the lower baseline average and smaller SD in patient-
reported symptoms at baseline reduces the amount of change that
could be observed in scores, as well as attenuating the observed
correlations with other ratings (Cohen et al. 2003).
Overall, the correlation between symptom severity change and
overall improvement in bipolar illness appeared to be stronger for
symptoms of mania than for those of depression. Moreover, corre-
lations between parent- and clinician-rated outcomes tended to be
greater for mania than for depressive symptoms. Two aspects may
partly account for the latter observations. First, the study population
was enriched for mania (YMRS total score ‡ 20 required for en-
rollment), leading to mania showing a stronger contribution to overall
clinical presentation. Second, despite the established antimanic ef-
fects of antipsychotics, fewer published data exist to substantiate their
efficacy in the treatment of depressive symptoms (Fountoulakis
2010). The smaller amount of improvement in depression symptoms
would contribute to correlations being of smaller magnitude.
The demonstrated relationship between the parent-reported GBI
and change in other measures of mania and depression symptom
severity suggests that the parent-GBI may provide a useful adjunct to
evaluating symptom response in clinical research, particularly in
situations in which clinicians have variable training (Garb 1998;
Mackin et al. 2006; Dubicka et al. 2008; Jenkins et al. 2011) or when
there are constraints on time or expense for assessment (Camara et al.
1998). Although agreement about most aspects of child behavior is
often low among parent, youth, and teacher (Achenbach et al. 1987;
Youngstrom et al. 2003; Carlson and Youngstrom 2011), consensus
is that obtaining cross-informant report about youth behavior adds
incremental value about severity (Carlson and Youngstrom 2003),
situational specificity of problems and functioning (De Los Reyes
and Kazdin 2005), and treatment response in clinical research. A
National Institute of Mental Health expert consensus paper advo-
cates using parent-reporting measures as a way of building a cross-
talk between research groups and studies, providing an information
source not subject to differences in clinical training or conceptuali-
zation (Nottelmann 2001). Present findings suggest potential value
for adding parent-reporting measures in studies of bipolar disorder,
not just for investigations of diagnosis and phenomenology, but also
for studies of treatment outcome (West et al. 2011). A further ar-
gument for the inclusion of parent-reporting measures as an adjunct
to clinician ratings is that parents are less likely than clinicians to
‘‘inflate’’ baseline scores in order to meet study inclusion criteria. In
addition to the value of parent ratings in clinical research, the rela-
tionship between parent ratings and other measures of bipolar
symptom severity also suggest that parent-reported measures may
have value in general clinical practice.
Another implication is that the Jacobson and Truax definitions
have been used to date in psychotherapy trials rather than in phar-
macological treatment studies ( Jacobson and Truax 1991). Although
the definitions used more commonly in pharmacological trials
produce higher response rates, they also result in higher placebo
response rates. Observed results suggest that it is essential to examine
in greater depth rather than simply comparing trials based on
‘‘response rate,’’ as choosing different definitions of response within
this single study yielded response rates ranging from 0% to 91%.
Although psychotherapy studies have adopted more stringent
standards, it has not been established whether these more stringent
definitions have greater validity when judged against criteria such as
consumer satisfaction, quality of life, or academic progress versus
simply being more conservative.
Limitations
Limitations of these analyses include the use of the YMRS scale,
which does not cover all of the DSM-IV defined symptoms of mania;
nor was the YMRS originally designed to be developmentally appro-
priate for children or adolescents (Fristad et al. 1992, 1995; Young-
strom et al. 2002). Results still support the use of the YMRS as an
outcome measure, although it is possible that other instruments could
be even more sensitive to treatment effects in this patient population.
Second, this was a brief study of acute treatment response; longer study
duration might provide a different picture regarding continued re-
sponse and potential response to depressive symptoms. It should also
be considered that differences between treatment groups at baseline
may have influenced the results; this was not specifically evaluated.
Finally, it would also be interesting for future studies to examine if the
pattern of clinically significant change was associated with premature
discontinuation from the treatment protocol.
Conclusions
In conclusion, this exploratory analysis of a large sample of
adolescents and children with bipolar I disorder demonstrates that
ARIPIPRAZOLE IN PEDIATRIC BIPOLAR I DISORDER 77
clinically meaningful definitions of response in acute treatment of a
manic or mixed episode include a 50% change in YMRS and a
composite measure of response, as well as others. Results also
provide evidence for the feasibility of implementing parent-
reported measures of symptom improvement to complement
clinician assessments.
The significant variability among definitions of response high-
lights a clear need for greater consensus among pediatric studies in
order to enable more effective assessment of treatment efficacy,
especially when the goal is not merely improvement on a scale but
an overall clinically meaningful response.
Clinical Significance
No consensus has been established regarding the agreed defi-
nitions of response and clinically significant change in treatment of
manic or mixed episodes associated with bipolar I disorder. Using a
range of definitions of response, this analysis showed considerable
variability in response rates, depending upon the choice of opera-
tional definition. Measurements based on parental responses were
generally better at detecting changes in symptom severity than were
measurements based on subject response.
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